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Introduction
An important relationship exists between tumor cells and their 
local extracellular microenvironment.1-4 Indeed, tumor-asso-
ciated stromal cells critically influence cancer progression and 
metastasis.1-4 Thus, tumor progression is the product of inter-
actions between cancer cells and adjacent stromal cells, such 
as immune cells, endothelia and fibroblasts, although the exact 
mechanism(s) still remain poorly understood.5-7
More specifically, stromal myo fibroblasts are now considered 
active metabolic drivers of tumor growth.8 In our recent studies, 
we proposed that stromal fibroblasts fuel epithelial tumor cells 
via a unilateral transfer of energy-rich nutrients from the tumor 
Migration stimulating factor (MSF) is a genetically truncated N-terminal isoform of fibronectin that is highly expressed 
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stroma to cancer cells.9 In accordance with this assertion, the 
recycled nutrients produced by stromal fibroblasts, via autoph-
agy/mitophagy, provide a steady-stream of energy-rich metabo-
lites to cancer cells, inducing mitochondrial biogenesis.10-15
Normal stromal fibroblasts are converted into carcinoma-
associated fibroblasts (CAFs) by complex interactions with adja-
cent cancer cells.5,16-19 These CAFs show a fetal-like phenotype, 
characterized by the expression of molecules typically expressed 
during embryonic development. In addition, CAFs develop 
a myofibroblast phenotype, with the expression of smooth 
muscle cell markers and the local production of transforming 
growth factor β (TGF-β), which can actively spread the CAF 
phenotype.20-26
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the behavior of many target cell populations (fibroblasts, vascular 
and epithelial cells) by stimulating migration/invasion, matrix 
remodelling and neo-angiogenesis.37-46
Here, we generated a new hTERT-immortalized fibroblast 
cell line overexpressing MSF in order to clarify the functional 
role of MSF in driving the cancer-associated fibroblast pheno-
type. Now, we demonstrate that MSF-expressing fibroblasts cre-
ate an autophagic/catabolic tumor stroma, which then provides 
high-energy nutrients to epithelial cancer cells via a paracrine 
mechanism.
Results
To directly assess the role of MSF in tumor growth, we stably 
overexpressed MSF in an immortalized human fibroblast cell 
line (hTERT-BJ1 cells) (Fig. 1A). Empty vector (Lv-105) control 
fibroblasts were produced in parallel. Figure 1A shows that trans-
duction with MSF lentiviral particles successfully increased the 
stable expression of the MSF protein.
Fibroblasts overexpressing MSF develop a cancer-associated 
fibroblast phenotype, characterized by the expression of myo-
fibroblast marker proteins and activated TGF-β signaling. 
Cancer-associated fibroblasts exhibit a myo fibroblastic pheno-
type, characterized by the synthesis of intracellular smooth mus-
cle markers, in particular α-smooth muscle actin (α-SMA). To 
evaluate if MSF expression promotes myo fibroblastic differentia-
tion, MSF-expressing fibroblasts were subjected to immunoblot 
analysis, using a panel of myo fibroblastic markers (Fig. 1A). The 
results show that MSF is indeed sufficient to induce the increased 
protein expression of SMA, Calponin (particularly, isoforms 1 
and 3) and Fibronectin (full-length).
Several lines of evidence indicate that activated fibroblasts 
increase their expression and secretion of TGF-β, thereby pro-
moting tumor growth. Thus, we next tested if MSF overexpres-
sion upregulates the expression of TGF-β. Consistent with this 
hypothesis, Figure 1B shows that MSF-overexpressing fibro-
blasts are characterized by an increase in TGF-β expression and 
a downregulation of its receptor, TGFβ-RI, both indicative of 
activated TGF-β signaling.
Fibroblasts overexpressing MSF migrate to a significantly 
greater extent than do control cells, and they also function as 
chemo-attractants, stimulating cancer cell migration. MSF is 
a potent motogenic factor, which is able to stimulate the migra-
tion of fibroblasts, epithelial as well as endothelial cells.35,46 Here, 
we demonstrate that MSF overexpression stimulates the migra-
tion of fibroblasts, validating the motogenic activity of the MSF 
protein (Fig. 2A). MSF could also influence the migration of 
cancer cells, by acting on these cells as a chemo-attractant. In 
support of this notion, Figure 2B shows that cancer cells, in the 
presence of MSF-overexpressing fibroblasts, migrate to a greater 
extent (1.4-fold) than do cancer cells in presence of normal con-
trol fibroblasts.
This migratory activity could be induced by the increased 
expression and/or activation of proteins that play a fundamental 
role in cytoskeletal organization. Small GTPases, such as Rac1 
and Cdc42, play a central role in regulating cell movement and 
Fetal-like fibroblasts and myo fibroblasts are also both viewed 
as “activated fibroblasts,” due to their increased expression of 
both ECM components and inflammatory cytokines.27-34 Fetal-
like fibroblasts also secrete a soluble, genetically truncated form 
of fibronectin, termed migration stimulating factor (MSF).27-34 
Interestingly, MSF is highly expressed in both fetal epithelial and 
stromal cells and in cancer patients, but its expression is somehow 
suppressed in normal adults.27-34
Detailed molecular characterization of MSF indicates that it 
is a 70-kDa protein that is essentially identical to the N-terminal 
domain of full-length fibronectin, with the addition of an MSF-
specific 10 amino-acid C-terminal sequence.35,36 MSF changes 
Figure 1. MSF overexpression confers the cancer-associated fibroblast 
phenotype, characterized by the expression of myo fibroblast markers 
and activated TGF-β signaling. (A) To assess the functional role of MSF 
stromal expression in tumor growth, we stably overexpressed the MSF 
protein in immortalized human fibroblast cell line (hTeRT-BJ1 cells). 
Successful overexpression of the MSF protein was verified by immunob-
lot analysis. empty vector control (Lv-105) or MSF fibroblasts were also 
subjected to immunoblot analysis with different myofibroblast marker 
proteins. equal protein loading was assessed by immunoblotting with 
β-actin. Note that MSF overexpression strongly induces the expression 
of myofibroblast markers such as α-SMA, calponin 1 and 3 and fibronec-
tin, while no increases in vimentin protein expression were observed in 
the fibroblasts. (B) MSF overexpression induces the activation of TGF-β 
signaling. Note that immunoblot analysis of control and MSF fibroblasts 
reveals that TGF-β ligand protein expression is significantly increased 
in MSF fibroblasts. Conversely, MSF fibroblasts are characterized by 
a reduction in the protein expression of TGFβ-RI (type I receptor), as 
compared with control fibroblasts.
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Note that MSF induces the activation of Akt-downstream 
effectors, such as phospho-mTOR and phospho-p70S6 kinase, 
both involved in protein biosynthesis. Akt normally activates 
Figure 2. MSF stimulates the migration of fibroblasts and acts as chemo-
attractant, stimulating cancer cell migration. (A) The migration of fibro-
blasts across an 8 μm pore uncoated membrane was assessed after a 6-h 
period, using a modified “Boyden Chamber” assay, employing Transwell 
cell culture inserts. Interestingly, the motility of fibroblasts overex-
pressing MSF was increased by ~3.4-fold, as compared with fibroblasts 
transfected with the empty-vector (Lv-105); p = 001 relative to control 
migration (Student’s t-test). (B) MSF overexpression stimulates cancer 
cell migration. To assess whether MSF fibroblasts can function as chemo-
attractants, MDA-MB-231 cells were placed in the upper chambers and 
fibroblasts [empty vector (Lv-105) fibroblasts or MSF fibroblasts] were 
seeded into the lower chambers. Note that MSF fibroblasts promote 
cancer cell migration by ~1.4-fold. p = 0.01, control vs. MSF fibroblasts 
(Student’s t-test). (C) MSF is sufficient to increase the expression of the 
two small GTpases, namely Rac1 and Cdc42. Cells [empty vector (Lv-105) 
fibroblasts or MSF fibroblasts] were subjected to immunoblot analysis. 
The loading control shown for (C) is the same as in Figure 1B, as the 
same nitrocellulose membrane(s) were stripped and re-probed.
migration by interacting with other proteins that more directly 
confer cytoskeletal rearrangements. As predicted, Figure 2C 
shows that MSF overexpression upregulates the expression levels 
of both these small-GTPases, which are associated with remodel-
ing the actin cytoskeleton.
Fibroblasts overexpressing MSF activate NFκB, exhibit the 
induction of autophagy and cell cycle arrest. Small GTPases are 
strong activators of the transcription factor NFκB,47,48 so we next 
validated that MSF is able to induce not only the upregulation 
of Cdc42 and Rac1, but also the activation of NFκB. As shown 
in Figure 3A, MSF overexpression resulted in increased levels of 
p-NFκB, suggesting that MSF could influence the stromal fibro-
blasts through the activation of a number of different signaling 
pathways, including the NFκB signaling pathway.
NFκB plays a pivotal role as a signal integrator, which con-
trols the autophagic process. For this purpose, we evaluated if 
the activation of NFκB in stromal MSF fibroblasts is sufficient 
to promote the autophagic process. Therefore, fibroblasts over-
expressing MSF were analyzed by immunoblot analysis, using 
a panel of autophagy markers. Figure 3B shows that MSF 
increases the expression of several classical autophagy mark-
ers, such as Beclin1, BNIP3 and LC3-I. These results suggest 
that MSF augments or activates the autophagic process in stro-
mal fibroblasts, probably via increased activation of the NFκB 
pathway. This pro-autophagic phenotype is associated with cell 
cycle arrest, as evidenced by the upregulation of CDK inhibi-
tors, such as p21(CIP1/WAF1), p19(ARF) and p16(INK4A) 
(Fig. 3C).
Under hypoxic conditions, MSF fibroblasts generate ele-
vated levels of L-lactate and show decreased mitochondrial 
activity, consistent with a shift toward glycolytic metabolism. 
We have previously shown that stromal fibroblasts promote and 
fuel tumor growth via activation of an autophagic program in 
the tumor stroma.8,9,12-15 Autophagy leads to the generation of 
recycled catabolic nutrients that can be used to power the ana-
bolic growth of cancer cells. Because L-lactate is a critical fuel 
that provides continued energetic support for cancer cells, we 
next examined if MSF fibroblasts are able to induce L-lactate 
accumulation. As shown in Figure 4A, fibroblasts overexpressing 
MSF display increased L-lactate production (~2-fold; p = 0.004; 
1.5-fold p = 0.03, values expressed as nmoles/μg or pmoles/cells, 
respectively). However, the ability of MSF fibroblasts to secrete 
L-lactate was observed only under hypoxic conditions.
That L-lactate accumulation is indicative of a shift toward 
predominantly glycolytic metabolism. This observation was vali-
dated by assessing the status of mitochondrial activity in MSF 
fibroblasts. Figure 4B shows decreased mitochondrial activity, as 
predicted, as visualized using MitoTracker staining. Note that 
MSF induces a dramatic reduction in MitoTracker staining, 
indicative of a loss of healty functional mitochondria, both under 
normoxic, as well as hypoxic conditions.
As shown in Figure 4C, MSF overexpression leads to Akt acti-
vation, which likely protects these cells against apoptosis. MSF 
fibroblasts were subjected to immunoblot analysis, using phos-
pho-specific antibodies directed against different protein compo-
nents of the Akt pathway.
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to promote tumor growth. For this purpose, we developed a 
human tumor xenograft model. MSF-overexpressing fibroblasts 
were co-injected with MDA-MB-231 breast cancer cells into the 
flanks of immunodeficient nude mice. Figure 5A demonstrates 
that MSF overexpression in stromal fibroblasts is sufficient to 
promote tumor growth, as evidenced by significant increases in 
both tumor weight and volume.
Stromal expression of MSF may contribute to tumor patho-
genesis by a number of mechanism(s), including the stimula-
tion of angiogenesis. To address this issue, frozen tissue sections 
derived from tumor xenografts were subjected to immunostain-
ing with a well-established vascular marker, namely CD31. As 
shown in Figure 5B, MSF overexpression in stromal fibroblasts 
does not have a significant effect on tumor neo-vascularization, 
indicating that the tumor-promoting effects of MSF in cancer-
associated fibroblasts are independent of tumor angiogenesis.
SMA, Rac1 and Cdc42 overexpression in fibroblasts induces 
myo fibroblast differentiation. We demonstrated above that 
MSF fibroblasts show increased expression of SMA and two 
small GTPase proteins, namely Rac1 and Cdc42. To deter-
mine if there is a cause-effect relationship here, we employed a 
genetic approach by overexpressing SMA, Rac1, and Cdc42 in 
an immortalized human fibroblast cell line (Fig. 6AC) Then, 
these fibroblast cell lines were subjected to immunoblot analysis, 
employing a panel of myo fibroblast markers, in order to charac-
terize their phenotype.
Note that Rac1- and Cdc42-overexpressing fibroblasts display 
the upregulation in SMA protein expression (Fig. 7A), and all 
three overexpressing cell lines show increases in the calponin and 
vimentin (Fig. 7B), consistent with a myo fibroblast phenotype. 
Similarly, both GTPases, Rac1 and Cdc42, were able to induce 
the reorganization of the F-actin cytoskeleton, as evidenced by 
an increase in the density of actin stress fibers, as visualized by 
Phalloidin staining (Fig. 7C); note the bundles of parallel fibers 
aligned along the cell axis.
Cdc42-overexpression induces NFκB-activation, with 
increased autophagy and a shift toward glycolytic metabo-
lism. Small GTPases are strong activators of the transcription 
factor NFκB.47,48 Thus, we evaluated the effects of expressing 
SMA, Rac1 and cdc42 in fibroblasts, on the status of NFκB 
and p-NFκB. Our results demonstrate that the p-NFκB protein 
levels are significantly increased only in Cdc42-overexpressing 
fibroblasts (Fig. 8A).
For this and all subsequent experiments, we chose to exam-
ine only the fibroblasts overexpressing SMA and Cdc42; SMA 
was used as a negative control and Cdc42 was used, as it is the 
GTPase that activates NFκB. To evaluate if this Cdc42-driven 
NFκB-activation promotes autophagy, fibroblasts overexpressing 
SMA and Cdc42 were subjected to immunoblot analysis, using a 
panel of autophagy markers.
Figure 8B demonstrates that Cdc42 overexpression in fibro-
blasts drives the increased expression of mitophagy (BNIP3) and 
autophagy markers (Beclin-1, LAMP1 and Cathepsin B).
Also, we evaluated if Cdc42-overexpressing fibroblasts 
are able to induce L-lactate accumulation and a shift toward 
glycolytic metabolism. Figure 8C demonstrates that Cdc42 
mTOR, leading to p70S6K activation. Activation of Akt pathway 
by MSF in stromal fibroblasts may lead to activation of protein 
synthesis, as a compensatory mechanism to prevent apoptotic cell 
death in cells undergoing constitutive autophagy/mitophagy.
Fibroblast overexpressing MSF promote tumor growth, 
without any increases in tumor angiogenesis. Because MSF 
fibroblasts are able to increase L-lactate production and have a 
strong autophagic phenotype, we evaluated whether MSF is able 
Figure 3. MSF overexpression in fibroblasts promotes the activation of 
NFκB, increases autophagy, and induces CDK inhibitors. (A) Since the 
human Rac-1 and Cdc42 proteins efficiently induce the transcriptional 
activity of nuclear factor kappaB (NF-kappaB), we next evaluated if MSF 
is able to induce not only the upregulation of the two small GTpases, 
but also the activation of NFκB. Note that immunoblot analysis of con-
trol or MSF fibroblasts revealed that the levels of p-NFκB are significant-
ly increased in MSF fibroblasts, as compared with control fibroblasts. 
(B) NFκB can induce autophagy, so we verified if activation of NFκB by 
MSF overexpressed fibroblasts is sufficient to induce autophagy. Cells 
were lysed and subjected to immunoblot analysis using antibodies di-
rected against a panel of autophagy markers. β-actin was used as equal 
loading control. Note that MSF increases the expression of several key 
autophagy markers, namely Beclin-1, BNIp3, and LC3-I. (C) To determine 
if MSF expression is also associated with senescence, we investigated 
whether known CDK inhibitors are upregulated. Immunoblot analysis 
shows that p21 (WAF1/CIp1), p19(ARF) and p16(INK4A) are all upregu-
lated, consistent with cell cycle arrest and/or the onset of senescence.
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of Cdc42 in stromal fibroblasts consistently promotes tumor 
growth, over a 25-d time course. Figure 9B shows that, at 4 
weeks post-injection, Cdc42 fibroblasts increased tumor volume 
by ~1.75-fold, as compared with vector-alone control fibroblasts 
cells, directly demonstrating that stromal Cdc42 is able to sup-
port tumor growth in vivo.
Finally, to determine the role of neo-vascularization in Cdc42-
mediated tumor growth, we quantified neo-vascularization via 
immunostaining with CD31 (Fig. 9C). However, a 25% increase 
of tumor angiogenesis in Cdc42 tumors is not sufficient to 
account for a near 2-fold increase in tumor growth. Instead, met-
abolic reprogramming of the tumor microenvironment toward 
L-lactate production is a more likely mechanism (Fig. 10).
expression is sufficient to induce an ~80% increase in L-lactate 
production, under hypoxic condition and after treatment with 
Metformin, a specific inhibitor of mitochondrial complex I. 
This shift toward glycolytic metabolism was further validated 
by MitoTracker staining, showing that Cdc42 expression 
strongly decreases mitochondrial activity under hypoxic condi-
tions (Fig. 8D).
Stromal expression of Cdc42 promotes increased tumor 
growth in vivo. To evaluate if Cdc42 expression in stromal cells 
is able to promote tumor growth in vivo, we used a human tumor 
xenograft model. Control, SMA or Cdc42 fibroblasts were co-
injected with MDA-MB-231 breast cancer cells in the flanks of 
immunodeficient nude mice. Figure 9A shows that overexpression 
Figure 4. MSF overexpression in fibroblasts induces a shift toward glycolytic metabolism. (A) Under hypoxic conditions, MSF fibroblasts secrete 
elevated levels of L-lactate, consistent with increased aerobic glycolysis. As shown in the figure, MSF fibroblasts secrete increased levels of L-lactate 
(~2-fold, p = 0.004; normalized for protein content; ~1.5-fold, p = 0.03; normalized for cell number), relative to control fibroblasts processed in paral-
lel. This suggests that MSF-overexpressing fibroblasts could provide essential energetic support for adjacent tumor epithelial cells, via the secre-
tion of L-lactate, which is a critical mitochondrial fuel for the tumor growth. (B) MSF overexpression induces a decrease in mitochondrial activity, 
as visualized using MitoTracker staining. Note that MSF decreases mitochondrial activity, both under normoxic condition (upper panels) and under 
hypoxic condition (lower panels). MitoTracker (red); nuclei/DApI (blue).original magnification, 60×. (C) MSF activates the Akt pathway. Control or MSF 
fibroblasts were subjected to immunoblot analysis with antibodies to phospho-Akt, phospho-mToR and phospho-p70 S6 kinase. The phospho-Akt, 
phospho-mToR and phospho-p70 S6 kinase immunoblots were then reprobed with Akt, mToR and p70 S6 kinase antibodies, respectively. Note that 
MSF overexpression is associated with Akt pathway activation. This reaction is probably an anti-apoptotic response, to protect the fibroblasts from 
autophagy-induced cell death.
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The expression of TGF-β, specifi-
cally TGF-β1, is upregulated in most 
tumors and seems to play a key role 
in cancer progression.3,18,19,49-52
Increased TGF-β expression in 
fibroblasts benefits cancer progres-
sion, likely via paracrine effects on 
tumor cells.18,19,49-52 In particular, 
the release of TGF-β in the vicin-
ity of cancer cells may result in a 
more hospitable microenvironment, 
facilitating tumor growth. Several 
authors have shown that TGF-β 
overexpression leads to an increased 
metabolic rate, due to enhanced 
glycolysis.53,54 MSF may induce gly-
colysis in stromal fibroblasts via 
increased endogenous production of 
TGF-β. The observed increase in 
glycolytic metabolism may be due to 
the autophagic destruction of mito-
chondria in MSF-overexpressing 
fibroblasts. This assertion is consis-
tent with our previous observations 
that autophagy in cancer-associated 
fibroblasts is able to generate a cata-
bolic tumor stroma that drives the 
anabolic growth of cancer cells.8,9 
Regardless of the exact mechanism 
activating glycolysis, MSF is able 
to produce a catabolic, energy-rich 
microenvironment that favors tumor 
growth.
Small GTPases, such as Rac1 and Cdc42, are known to 
play a critical role in cell migration and invasion.55,56 However, 
their potential roles in myo fibroblast differentiation, autophagy 
and cellular metabolism are underappreciated. In the current 
study, we demonstrated that MSF-overexpressing fibroblasts 
have increased expression both Rac1 and Cdc42. To determine 
whether increased Rac1 and/or Cdc42 expression influences the 
activation of tumor microenvironment, we generated Rac1- and 
Cdc42-overexpressing fibroblasts.
Our results demonstrate that both Rac1 and Cdc42 fibro-
blasts undergo myo fibroblast differentiation, with characteristic 
re-organization of the actin cytoskeleton. However, only Cdc42 
fibroblasts show activation of NFκB, with the onset of autoph-
agy and a shift toward predominantly glycolytic metabolism in 
the tumor stroma resulting in the promotion of tumor growth. 
Therefore, overexpression and/or activation of Cdc42 is a likely 
mechanism by which MSF induces NFκB-activation, leading to 
increased autophagy and glycolysis due to reduced mitochon-
drial function. As such, glycolytic/catabolic MSF fibroblasts cre-
ate a favorable metabolic microenvironment to support tumor 
growth.
In conclusion, our results highlight the critical functional role 
of MSF as a driver of cancer progression. This is consistent with 
Discussion
The role of the host stromal microenvironment in promoting 
tumor initiation and progression is now well-established.1-4 
However, the exact molecular mechanism(s) of how cancer-
associated fibroblasts promote tumor growth remain unknown. 
Here, we highlight that MSF (migration-stimulating factor) 
functions to metabolically reprogram stromal fibroblasts toward 
glycolytic metabolism, resulting in the generation of a catabolic 
tumor microenvironment that actively “fuels” anabolic tumor 
growth.
More specifically, MSF-overexpressing fibroblasts were used 
to mimic the “activated microenvironment” that is now widely 
known to support tumor growth. We demonstrated that MSF 
fibroblasts show many characteristics of differentiated myo 
fibroblasts, including the expression of smooth muscle-specific 
proteins.
Transforming growth factor-β (TGF-β) is a potent inducer 
of myo fibroblast differentiation that has been implicated in con-
ferring the tumor-associated fibroblast phenotype.3,18,19,49-52 Here, 
we have demonstrated that MSF overexpression in stromal fibro-
blasts leads to the increased production of TGF-β and is associ-
ated with a reduction in the expression of its receptor, TGF-β-RI. 
Figure 5. MSF overexpression in fibroblasts dramatically promotes breast cancer tumor growth, with-
out affecting tumor angiogenesis. (A) Control or MSF fibroblasts were co-injected with MDA-MB-231 
breast cancer cells into the flanks of nude mice. After 4 weeks post-injection, the resulting tumors were 
harvested. Interestingly, relative to control fibroblasts (Lv-105), MSF fibroblasts increased tumor weight 
by ~2.5-fold (p = 0.03) and tumor volume by ~4-fold (p = 0.01). n = 10 tumors per experimental group. 
(B) MSF overexpressing fibroblasts do not increase tumor angiogenesis. Frozen tumor sections were im-
munostained with anti-CD31 antibodies to quantify vessel density. As shown in the figure, note that the 
tumor promoting effect of MSF fibroblasts are independent of angiogenesis, as no significant increases 
in vessel density were observed.
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(Santa Cruz, sc-759); p21 (Santa Cruz, sc-6246); LAMP1 (Santa 
Cruz, sc-17768); cathepsin B (Santa Cruz, sc-13985).
Cell culture and stable transfection. Human immortalized 
fibroblasts (hTERT-BJ1) were used to generate the cell lines 
overexpressing migration-stimulatory factor (MSF), SMA, Rac1 
and Cdc42. Lentiviral plasmids [EX-NEG-Lv105 (empty vec-
tor), Ex- Z4998-Lv105 (human MSF), Ex-D0101-Lv105 (human 
SMA), Ex-A0247-Lv105 (human Rac1), Ex-X0047-Lv105 
(human cdc42) (obtained from GeneCopoeia, Inc.)] were used 
to transfect GeneCopoeia 293Ta lentiviral packaging cells using 
Lenti-PacTM HIV Expression Packaging Kit following the man-
ufacturer’s instructions. After 48 h, lentivirus containing culture 
its ability to stimulate the migration/invasion in both stromal 
and tumor cells and with its effects on the metabolic remodeling 
of the tumor microenvironment.
Materials and Methods
Materials. Reagents were purchased as follows: the specific 
and cell-permeable proteasome inhibitor (MG132) was from 
Calbiochem (used at a final concentration of 10 μM for 16h); 
Metformin (1.1-dimethylbiguanide hydrochloride) was from 
Sigma (D150959); Alexa Fluor 633 Phalloidin (A222284) was 
from Invitrogen. Antibodies to the following target proteins were 
also used: Fibronectin N-terminal (Chemicon International, 
MAB1936; to recognize MSF); Fibronectin (Abcam, ab23750); 
Vimentin (BD PharMingen, 550513); Calponin 1/2/3 (Santa 
Cruz Biotech, sc-28545); Smooth Muscle Actin (Dako, M0851); 
Beclin (Novus Biologicals, NBP1–00085); BNIP-3 (Abcam, 
ab10433); LC3 (Abcam, ab48394); β-actin (Sigma-Aldrich, 
A5441); TGF-β (Cell Signaling, 3711); TGF-β-RI (Santa Cruz 
Biotech, sc-398); phospho-Akt (Cell Signaling, 9271); Akt 
(Cell Signaling, 2967); phospho-mTOR (Cell Signaling, 2971); 
mTOR (Cell Signaling, 2972); phospho-p70 S6 kinase (Cell 
Signaling, 9234); p70 S6 kinase (Cell Signaling, 9202); CD31 
(BD Biosciences, 550274); Rac1 (Santa Cruz, sc-95); Cdc42 
(Santa Cruz, sc-8401); p-NFκB (Cell Signaling, 3037); NFκB 
(Cell Signaling, 3034); p14ARF (Santa Cruz, sc-53639); p16 
Figure 6. Recombinant expression of SMA, Rac1, and Cdc42 in im-
mortalized fibroblasts. To assess the role of SMA, Rac1, and Cdc42 in 
the tumor microenvironment, we stably overexpressed SMA, Rac1, 
and Cdc42 in the immortalized human fibroblast cell line (hTeRT-BJ1 
cells). Successful protein overexpression of SMA, Rac1, and Cdc42 was 
validated by immunoblot analysis (A–C). In order to better visualize 
Cdc42 and Rac1 overexpression, we treated fibroblasts with a protease 
inhibitor (MG132; 10 μM for 16 h).
Figure 7. overexpression of SMA, Rac1, and Cdc42 confers the myo 
fibroblast phenotype. (A) Rac1- and Cdc42- overexpressing fibroblasts 
display the upregulation of SMA protein expression. (B) Rac1 and 
Cdc42induce the expression of other myofibroblast markers, namely 
calponin and vimentin. (C) Rac1 and Cdc42 regulate the organization 
of the actin cytoskeleton, inducing a reorganization of F-actin, as sug-
gested by the increase of actin stress fibers. equal cell numbers were 
plated on glass cover sides, and after 24 h, the cells were fixed and 
actin filaments and nuclei were stained with phalloidin (red) and DApI 
(blue), respectively. Note that SMA-, Rac1- and Cdc42- overexpressing 
fibroblasts display an increased number of stress fibers, as compared 
with vector-alone control cells.
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All cell lines used in the following experi-
ments were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 
10% fetal bovine serum in a 37°C humidified 
atmosphere (5% CO
2
) unless otherwise noted.
Immunoblot analysis. For immunoblot-
ting, cultured cells were harvested in lysis buf-
fer (10 mM Tris, pH 7.5, 150 mM NaCl, 1% 
Triton X-100, and 60 mM n-octyl-glucoside) 
or RIPA lysis buffer containing protease inhib-
itors (Roche, 11836153001) and phosphatase 
inhibitors (Thermoscientific, 78420). The 
pooled cells were rotated for 40 min at 4°C, 
centrifuged at 10.000 × g for 15 min at 4°C, 
and the protein concentration of the superna-
tant was determined using the BCA reagent 
(Pierce). Protein samples (30–50 μg total pro-
teins per lane) were then subjected to 12% or 
15% SDS-PAGE, and the proteins were then 
electrophoretically transferred to a nitrocel-
lulose membrane. After blocking for 1 h at 
room temperature with TBST (10 mM Tris, 
pH 8.0, 150 mM NaCl, 0.05% Tween 20) 
supplemented with 5% nonfat dry milk and 
1% BSA, membranes were incubated for 1 h 
at room temperature with primary antibodies 
and then for 1 h at RT with specific (HRP)-
conjugate secondary antibodies [anti-mouse, 
1:6,000 dilution (Pierce) or anti-rabbit, 
1:5,000 dilution (BD PharMingen)]. HRP 
activity was visualized by enhanced chemilu-
minescent substrate (Thermo Scientific) fol-
lowed by exposure of the membrane to X-ray 
film.
Migration assay. The effects of MSF 
overexpression on fibroblast migration and 
the effects of MSF fibroblasts on the migra-
tory potential of MDA-MB-231 cells were 
measured in vitro using a modified Boyden 
chamber assay. Briefly, fibroblasts [EV 
(empty vector) or MSF overexpressing] in 
0.5 ml of serum-free Dulbecco’s modified 
Eagle’s medium were added to the wells of 
8 μm pore uncoated membrane of modified 
Boyden chambers. The lower chambers con-
tained 10% fetal bovine serum in Dulbecco’s 
modified Eagle’s medium to serve as a chemo-
attractant. Cells were incubated at 37°C and 
allowed to migrate throughout the course of 
6 h. To assess the effect of fibroblast overex-
pressing MSF protein on the migratory capac-
ity of MDA-MB-231 cells, fibroblasts were 
seeded in the lower chambers in DMEM 
supplemented with 10% NuSerum and used as chemo-attrac-
tant. MDA-MB-231 cells were added to the wells of 8 μm pore 
uncoated membrane of modified Boyden chambers and allowed 
medium was added to human fibroblasts in the presence of 5 μg/
ml Polybrene. Infected fibroblasts were selected with puromycin 
(1.5 μg/ml).
Figure 8. Cdc42-overexpression promotes the activation of NFκB, induces increased autoph-
agy and glycolytic metabolism. (A) GTpases are strong activators of the transcription factor 
NFκB. As shown in figure, note that immunoblot analysis of control or SMA-, Rac1- and cdc42- 
overexpressing fibroblasts reveals that p-NFκB protein levels are significantly increased, ex-
clusively in Cdc42 fibroblasts, as compared with control fibroblasts. (B) To validate that Cdc42 
induces an autophagic program, cells were subjected to immunoblot analysis using several 
autophagy markers. β-actin was used as an equal loading control. Note that Cdc42 increases 
the expression of the autophagy markers, such as Beclin-1, BNIp3, LAMp-1 and Cathepsin B 
(37kDA). (C) Cdc42-overexpressing fibroblasts display a predominantly glycolytic metabolism, 
as demonstrated by increased L-Lactate production, under hypoxic conditions. Cells cultured 
for 48 h under hypoxic conditions (0.5% o2) were treated with or without metformin (1 mM), 
and the results are expressed as ratio between treated vs. untreated cells. (D) The shift toward 
a predominantly glycolytic metabolism is also demonstrated by decreased mitochondrial 
activity, as visualized using MitoTracker. Note that Cdc42 significantly decreases mitochon-
drial activity, as compared with vector alone control or SMA overexpressing fibroblasts. 
MitoTracker (red); nuclei/DApI (blue). original magnification, 60x.
www.landesbioscience.com Cell Cycle 3411
to migrate throughout the course of 4 h at 37°C. In both cases, 
cells were removed from the upper surface of the membrane by 
scrubbing with cotton swabs. Chambers were stained in 0.5% 
crystal violet diluted in 100% methanol for 30 min, rinsed in 
water and examined under a bright-field microscope. Values for 
migration were obtained by counting five fields per membrane 
(X20 objective) and represent the average of three independent 
experiments.
L-lactate assay. Cells (empty vector or MSF-, SMA-, Cdc42- 
overexpressing fibroblasts) were seeded in quadruplicate (100,000 
cells per well) in 12-well plates in 1 ml of complete media. After 
18 h, the media was changed to DMEM containing 2% FBS and 
incubated under hypoxic conditions (0.5% O
2
). SMA and cdc42 
overexpressing fibroblasts were also with or without metformin 
(1 mM). After 48 h, the media of each well was collected and the 
concentration of L-lactate was measured using the EnzyChrom™ 
L-Lactate Assay Kit (ECLC-100, BioAssay Systems, Inc.). After 
removing the media, cells were tyrpsinized, spundown and resus-
pended in 1 mL of media for quantification. Cells were counted 
in 4–6 fields, using a 40× objective lens and a hemocytometer. 
Cells were then lysed, and the protein concentration was deter-
mined using the BCA reagent (Pierce). The amount of L-lactate 
in the media was normalized to total cell number or to total cell 
protein content.
Mitochondrial staining. To evaluate mitochondrial activ-
ity, cells were stained with MitoTracker Orange (CMTMRos; 
M7510, Invitrogen, Inc.). Lyophilized MitoTracker was dis-
solved in DMSO to generate a 1 mM stock solution that was 
then diluted into serum-free DMEM at a final concentration of 
25 nM. Briefly, control or MSF-, SMA-, Cdc42-overexpressing 
fibroblasts (90,000 cells per well) were cultured for 48 h in nor-
moxia or under hypoxic conditions. Then, they were incubated 
with pre-warmed MitoTracker staining solution for 12 min at 
37°C in the dark. Cells were then washed in PBS Ca2+/Mg2+, 
three times and fixed with 2% PFA 30 min a RT. Cell were 
washed again with PBS Ca2+/Mg2+, incubated with the nuclear 
stain DAPI and mounted.
Murine xenograft studies. All animals were housed and 
maintained in a barrier facility at the Kimmel Cancer Center at 
Thomas Jefferson University under National Institutes of Health 
(NIH) guidelines. Mice were kept on a 12-h light/dark cycle with 
ad libitum access to food and water. Animal protocols used for 
this study were pre-approved by the Institutional Animal Care 
and Use Committee (IACUC). Briefly, MDA-MB-231-GFP 
human breast cancer cells (1 × 106 cells) were co-injected with 
control (empty vector) or MSF-, SMA-, Cdc42- overexpressing 
fibroblasts (3 × 105 cells) in 100 μl of sterile PBS into the flanks of 
athymicNCr nude mice (NCRNU; Taconic Farms; 6–8 weeks of 
age). Mice were then sacrificed at 4 weeks post-injection; tumors 
were dissected to determine their weight and size using calipers. 
Tumor volume was calculated using the formula (X2Y)/2, where 
X and Y are the short and long dimensions, respectively, of the 
tumor. After the dissection, tumors were fixed with 10% forma-
lin or flash-frozen in liquid nitrogen-cooled isopentane.
Quantitation of tumor angiogenesis. Immunohistochemical 
staining for CD31 was performed on frozen tumor sections using 
Figure 9. Cdc42 overexpressing fibroblasts promote tumor growth in 
vivo. We used a xenograft model employing MDA-MB-231 breast cancer 
cells injected into the flanks of athymic nude mice. MDA-MB-231 breast 
cancer cells were co-injected with either the empty vector (Lv-105), 
SMA- or Cdc42- overexpressing fibroblasts. (A) Comparative trend mea-
surements for tumor growth (days 7–25 post-injection). Tumor volumes 
were measured with callipers about twice a week and mean tumor 
volume is plotted vs. time, for each experimental group. (B) Tumor 
growth. Tumor volumes were also measured at 4 weeks post-injection. 
Note that fibroblasts overexpressing Cdc42 significantly promote tumor 
growth, resulting in a 1.75-fold increase in tumor volume. p = 0.01; n = 
10 tumors per experimental group. (C) Tumor angiogenesis. Tumor fro-
zen sections were cut and immunostained with anti-CD31 antibodies. 
Then, vascular density (number of vessels per field) was quantified. The 
observed 25% increase in tumor angiogenesis in Cdc42 tumors is not 
sufficient to account for a near 2-fold increase in tumor growth. Instead, 
metabolic reprogramming of the tumor microenvironment, toward 
L-lactate production, is a more likely mechanism.
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with TBP buffer (0.1% Triton X-100, 0.2% 
BSA in PBS Ca2+/Mg2+. The cells were stained 
with Phalloidin Staining Solution (diluted 
1:40 in PBS 1% BSA) 30 min at RT in dark 
conditions. Stained F-actin was visualized 
using a Zeiss LSM510 meta-confocal system. 
Images were acquired with a 20× objective.
Statistical analysis. Statistical signifi-
cance was examined using the Student’s t-test. 
Values of p ≤ 0.05 were considered significant. 
Values were expressed as means ± SEM.
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a three step biotin-streptavidin-horseradish peroxidase method. 
Frozen tissue sections (6 μm) were fixed in 4% paraformalde-
hyde in PBS for 10 min and washed with PBS. After blocking 
with 10% rabbit serum, the sections were incubated overnight 
at 4°C with rat anti-mouse CD31 antibody (BS Biosciences) at 
a dilution of 1:200, followed by biotinylated rabbit anti-rat IgG 
(Vector Labs, 1:200) antibody and streptavidin-HRP (Daki, 
1:1000). Immunoreactivity was revealed with 3,3'-diaminoben-
zidine (DAB).
Phalloidin staining. Cell monolayers were stained with Alexa 
Fluor 633-phalloidin to examine the structure of filamentous 
F-actin. Washed cells were fixed with paraformaldehyde 2%, 
washed again with PBS Ca2+/Mg2+ and permeabilized for 10 min 
Figure 10. MSF expression in cancer-associated fibroblasts drives tumor growth. MSF leads 
to the upregulation of SMA and a number of other myo fibroblast marker proteins, conferring 
a myo fibroblast phenotype. The fibroblast activation by MSF is probably induced by TGF-β 
signaling and the increased expression of the small GTpase Cdc42, driving the activation of 
NFκB that, in turn, induces autophagy, mitophagy and aerobic glycolysis, thereby promoting 
tumor growth.
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